GeneDx Holdings Corp. Research and Development Expense
GeneDx Holdings Corp. (WGS) reported Research and Development Expense of $19.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- GeneDx Holdings Corp. research and development expense for the quarter ending 2026-06-30 was $19.66M, a 30.35% increase year-over-year.
- GeneDx Holdings Corp. research and development expense for the quarter ending 2026-03-31 was $19.80M, a 57.46% increase year-over-year.
- GeneDx Holdings Corp. research and development expense for the quarter ending 2025-12-31 was $24.54M, a 111.78% increase year-over-year.
- GeneDx Holdings Corp. research and development expense for the quarter ending 2025-09-30 was $19.83M, a 69.99% increase year-over-year.
- GeneDx Holdings Corp. research and development expense for fiscal 2025 was $72.03M, a 57.53% increase from fiscal 2024.
- GeneDx Holdings Corp. research and development expense for fiscal 2024 was $45.72M, a 21.53% decline from fiscal 2023.
- GeneDx Holdings Corp. research and development expense for fiscal 2023 was $58.27M, a 32.41% decline from fiscal 2022.
- GeneDx Holdings Corp. research and development expense for fiscal 2022 was $86.20M, a 18.03% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.66M 10-Q · filed 2026-08-03 | $39.46M 10-Q · filed 2026-08-03 | $64.00M derived: sum of 3 quarters · filed 2026-08-03 | $83.83M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $19.80M 10-Q · filed 2026-05-04 | $44.34M derived: sum of 2 quarters · filed 2026-05-04 | $64.17M derived: sum of 3 quarters · filed 2026-05-04 | $79.25M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $24.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $44.37M derived: sum of 2 quarters · filed 2026-02-23 | $59.45M derived: sum of 3 quarters · filed 2026-08-03 | $72.03M 10-K · filed 2026-02-23 |
| 2025-09-30 | $19.83M 10-Q · filed 2025-10-28 | $34.91M derived: sum of 2 quarters · filed 2026-08-03 | $47.48M 10-Q · filed 2025-10-28 | $59.07M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $15.08M 10-Q · filed 2026-08-03 | $27.66M 10-Q · filed 2026-08-03 | $39.24M derived: sum of 3 quarters · filed 2026-08-03 | $50.91M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $12.58M 10-Q · filed 2026-05-04 | $24.16M derived: sum of 2 quarters · filed 2026-05-04 | $35.83M derived: sum of 3 quarters · filed 2026-05-04 | $46.73M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $11.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $23.25M derived: sum of 2 quarters · filed 2026-02-23 | $34.16M derived: sum of 3 quarters · filed 2026-02-23 | $45.72M 10-K · filed 2026-02-23 |
| 2024-09-30 | $11.66M 10-Q · filed 2025-10-28 | $22.57M derived: sum of 2 quarters · filed 2025-10-28 | $34.13M 10-Q · filed 2025-10-28 | $46.38M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $10.90M 10-Q · filed 2025-07-29 | $22.47M 10-Q · filed 2025-07-29 | $34.72M derived: sum of 3 quarters · filed 2026-02-23 | $49.01M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $11.57M 10-Q · filed 2025-04-30 | $23.82M derived: sum of 2 quarters · filed 2026-02-23 | $38.10M derived: sum of 3 quarters · filed 2026-02-23 | $55.24M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $12.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $26.54M derived: sum of 2 quarters · filed 2026-02-23 | $43.67M derived: sum of 3 quarters · filed 2026-02-23 | $58.27M 10-K · filed 2026-02-23 |
| 2023-09-30 | $14.29M 10-Q · filed 2024-10-29 | $31.43M derived: sum of 2 quarters · filed 2024-10-29 | $46.02M 10-Q · filed 2024-10-29 | $70.38M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $17.14M 10-Q · filed 2024-07-30 | $31.73M 10-Q · filed 2024-07-30 | $56.10M derived: sum of 3 quarters · filed 2024-07-30 | $69.45M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | $14.59M 10-Q · filed 2024-04-29 | $38.96M derived: sum of 2 quarters · filed 2024-04-29 | $52.31M derived: sum of 3 quarters · filed 2024-04-29 | $79.48M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $24.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $37.72M derived: sum of 2 quarters · filed 2024-02-23 | $64.89M derived: sum of 3 quarters · filed 2024-02-23 | $86.20M 10-K · filed 2024-02-23 |
| 2022-09-30 | $13.35M 10-Q · filed 2023-11-03 | $40.52M derived: sum of 2 quarters · filed 2023-11-03 | $61.84M 10-Q · filed 2023-11-03 | $84.08M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $27.17M 10-Q · filed 2023-08-08 | $48.48M 10-Q · filed 2023-08-08 | $70.73M derived: sum of 3 quarters · filed 2023-08-08 | $88.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $21.32M 10-Q · filed 2023-05-09 | $43.56M derived: sum of 2 quarters · filed 2023-05-09 | $61.39M derived: sum of 3 quarters · filed 2023-05-09 | $73.34M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $22.25M 10-K · filed 2022-03-14 | $40.08M derived: sum of 2 quarters · filed 2022-11-14 | $52.03M derived: sum of 3 quarters · filed 2022-11-14 | $105.16M 10-K · filed 2023-03-16 |
| 2021-09-30 | $17.83M 10-Q · filed 2022-11-14 | $29.78M derived: sum of 2 quarters · filed 2022-11-14 | $82.92M 10-Q · filed 2022-11-14 | $114.08M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $11.95M 10-Q · filed 2022-08-15 | $65.08M 10-Q · filed 2022-08-15 | $96.25M derived: sum of 3 quarters · filed 2022-08-15 | $115.33M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $53.13M 10-Q · filed 2022-05-12 | $84.29M derived: sum of 2 quarters · filed 2022-05-12 | $103.38M derived: sum of 3 quarters · filed 2022-05-12 | $112.74M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $31.16M 10-K · filed 2022-03-14 | $50.24M derived: sum of 2 quarters · filed 2022-03-14 | $59.60M derived: sum of 3 quarters · filed 2022-03-14 | $72.70M 10-K · filed 2023-03-16 |
| 2020-09-30 | $19.08M 10-K · filed 2022-03-14 | $28.44M derived: sum of 2 quarters · filed 2022-03-14 | $41.54M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $9.36M 10-K · filed 2022-03-14 | $22.46M derived: sum of 2 quarters · filed 2022-03-14 | ||
| 2020-03-31 | $13.10M 10-K · filed 2022-03-14 | |||
| 2019-12-31 | $34.91M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |